Miraki Innovation, a Cambridge-based investment firm, has introduced a USD175 million Medical Technology Breakthrough Fund to assist finance and develop the next generation of innovative medtech companies. As per the report, the Medical Technology Breakthrough Fund will also support the company’s mission of recognizing and solving the world’s most pressing health challenges through technology.
This is the third fund for Miraki’s founder, Chris Velis, where the company utilizes Chris’ unique, proficient and proven approach to investing that has led to the creations and exits of over 16 industry-leading companies so far. As part of the announcement, the team at Miraki will utilize capital from the new fund to develop and support portfolio companies, transforming ideas and research out of leading research labs and academic institutions, and creating them into flourishing companies in the MedTech epicenter of Cambridge, Massachusetts.
Miraki Founder Chris Velis said that “With global concerns like growing antibiotic resistance that continue to strain healthcare resources, it’s more critical than ever that we advance medtech investment to bring more cutting-edge research to patients.” According to him, “Our methodology builds and brings companies to market quickly and efficiently. By taking quantum leaps – not by making incremental improvements – we intend to bring returns to investors while improving and saving lives.”
Rolled out with comprehending and expecting global healthcare needs, threats, opportunities, and demands, Miraki Innovation is the science of investing and entrepreneurship. The company brings together innovations from top research agencies, top-tier academic institutions, and in-house experts to solve those challenges.